Literature DB >> 26080810

Polymeric Drug-Delivery Systems: Role in P-gp Efflux System Inhibition.

Preeti Gupta1, Tarun Garg2, M Tanmay1, Saahil Arora3.   

Abstract

Permeability glycoprotein (P-gp), a multispecific drug transporter belonging to the multidrug resistance (MDR) gene subfamily, is mainly responsible for efflux of diffused intracellular drugs, resulting in poor drug bioavailability. P-gp is overexpressed in the blood-brain barrier, gastrointestinal tract (GIT), kidney, liver, pancreas, and cancerous cells, leading to multidrug resistance and failure of therapy. Because P-gp is transported into cells by way of receptor-mediated endocytosis (in contrast to diffusion for free drug), polymeric efflux pump modulators can have a major role in efficient drug delivery. Various polymer drug conjugates that have been proven to provide potential treatments in MDR cases are reviewed here, with an emphasis on the role of the P-gp efflux pump, bioavailability, and the mechanism of inhibition of the P-gp transporter by various polymers and delivery systems. This review also highlights the potential of specific polymer drug conjugates to act as P-gp efflux pump inhibitors to provide enhanced bioavailability and therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26080810     DOI: 10.1615/critrevtherdrugcarriersyst.2015011592

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  7 in total

Review 1.  Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer.

Authors:  Lu Huang; Zhi Liao; Zhixi Liu; Yan Chen; Tingwenli Huang; Hongtao Xiao
Journal:  Front Pharmacol       Date:  2022-05-10       Impact factor: 5.988

2.  Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.

Authors:  María Carmen Leiva; Raúl Ortiz; Rafael Contreras-Cáceres; Gloria Perazzoli; Iryna Mayevych; Juan Manuel López-Romero; Francisco Sarabia; Jose Manuel Baeyens; Consolación Melguizo; Jose Prados
Journal:  Sci Rep       Date:  2017-10-18       Impact factor: 4.379

3.  Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2.

Authors:  Peng Xu; Hua Zhou; Ya-Zhuo Li; Zhong-Wen Yuan; Chang-Xiao Liu; Liang Liu; Ying Xie
Journal:  Front Pharmacol       Date:  2018-10-26       Impact factor: 5.810

4.  Poloxamer-188 and d-α-Tocopheryl Polyethylene Glycol Succinate (TPGS-1000) Mixed Micelles Integrated Orodispersible Sublingual Films to Improve Oral Bioavailability of Ebastine; In Vitro and In Vivo Characterization.

Authors:  Nayyer Islam; Muhammad Irfan; Salah-Ud-Din Khan; Haroon Khalid Syed; Muhammad Shahid Iqbal; Ikram Ullah Khan; Amina Mahdy; Mohamed Raafat; Mohammad Akbar Hossain; Sana Inam; Rabia Munir; Memoona Ishtiaq
Journal:  Pharmaceutics       Date:  2021-01-04       Impact factor: 6.321

5.  In Silico Drug Repurposing of FDA-Approved Drugs Highlighting Promacta as a Potential Inhibitor of H7N9 Influenza Virus.

Authors:  Sphamandla E Mtambo; Hezekiel M Kumalo
Journal:  Molecules       Date:  2022-07-15       Impact factor: 4.927

6.  Sericin nanomicelles with enhanced cellular uptake and pH-triggered release of doxorubicin reverse cancer drug resistance.

Authors:  Weihong Guo; Lizhi Deng; Jiang Yu; Zhaoyu Chen; Yanghee Woo; Hao Liu; Tuanjie Li; Tian Lin; Hao Chen; Mingli Zhao; Liming Zhang; Guoxin Li; Yanfeng Hu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 7.  State of the art of overcoming efflux transporter mediated multidrug resistance of breast cancer.

Authors:  Qingqing Huang; Tiange Cai; Li Bai; Yinghong Huang; Qianwen Li; Qi Wang; Peter Chiba; Yu Cai
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.